Pharma Stability: Insights, Guidelines, and Expertise
A stability dossier provides comprehensive data about the product’s shelf life, degradation profile, storage conditions, and packaging integrity. This includes long-term, intermediate, and accelerated study results with appropriate justification of storage conditions based on ICH Climatic Zones (I–IVb).
Click to read the full article.
Each agency plays a unique role in shaping global expectations for pharmaceutical stability testing. Here’s a breakdown:
Click to read the full article.
A multi-region stability study is a coordinated program that generates stability data under various environmental conditions to support drug registration in multiple regulatory jurisdictions. It considers different climatic zones (I–IVb), packaging types, shelf life expectations, and regulatory formats.
Click to read the full article.
Before assembling your submission dossier, verify that you have the complete set of data and documents for each product strength and packaging configuration:
Click to read the full article.
The ICH has classified the world into distinct zones based on long-term average temperature and humidity profiles. Each zone dictates specific conditions that a pharmaceutical product must withstand to ensure stability throughout its shelf life.
Click to read the full article.
The CTD is a set of standardized documents used for marketing authorization applications across ICH regions and beyond. It includes five modules:
Click to read the full article.
Agencies require stability studies under conditions reflecting their regional climatic zones. However, these zones vary in terms of temperature and humidity requirements.
Click to read the full article.
The lifecycle model treats stability testing as a continuous process tied to the product’s entire commercial lifespan. It involves:
Click to read the full article.
Determine the ICH climatic zones applicable to your target markets and ensure real-time data generation accordingly:
Click to read the full article.
One of the most common causes for WHO or CDSCO rejections is the absence of Zone IVb data (30°C/75% RH). Companies often submit only Zone II or III data, assuming ICH Q1A coverage is sufficient.
Click to read the full article.